204 related articles for article (PubMed ID: 27432604)
1. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
2. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.
Daley P; Louie T; Lutz JE; Khanna S; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
J Antimicrob Chemother; 2017 Dec; 72(12):3462-3470. PubMed ID: 28961905
[TBL] [Abstract][Full Text] [Related]
3. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
[TBL] [Abstract][Full Text] [Related]
4. Surotomycin (A Novel Cyclic Lipopeptide) vs. Vancomycin for the Treatment of Clostridioides difficile Infection: A Systematic Review and Meta-analysis.
Muhammad A; Madhav D; Rawish F; Viveksandeep TC; Albert E; Mollie J; Prateek S
Curr Clin Pharmacol; 2019; 14(3):166-174. PubMed ID: 30924421
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of surotomycin for the treatment of Clostridium difficile.
Knight-Connoni V; Mascio C; Chesnel L; Silverman J
J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection.
Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH
J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA
Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357
[TBL] [Abstract][Full Text] [Related]
9. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
10. Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With
Boix V; Fedorak RN; Mullane KM; Pesant Y; Stoutenburgh U; Jin M; Adedoyin A; Chesnel L; Guris D; Larson KB; Murata Y
Open Forum Infect Dis; 2017; 4(1):ofw275. PubMed ID: 28480267
[TBL] [Abstract][Full Text] [Related]
11. Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Gerding DN; Cornely OA; Grill S; Kracker H; Marrast AC; Nord CE; Talbot GH; Buitrago M; Gheorghe Diaconescu I; Murta de Oliveira C; Preotescu L; Pullman J; Louie TJ; Wilcox MH
Lancet Infect Dis; 2019 Mar; 19(3):265-274. PubMed ID: 30709665
[TBL] [Abstract][Full Text] [Related]
12. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.
Chandorkar G; Zhan Q; Donovan J; Rege S; Patino H
BMC Pharmacol Toxicol; 2017 Mar; 18(1):24. PubMed ID: 28347318
[TBL] [Abstract][Full Text] [Related]
15. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
16. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
Mullane K; Lee C; Bressler A; Buitrago M; Weiss K; Dabovic K; Praestgaard J; Leeds JA; Blais J; Pertel P
Antimicrob Agents Chemother; 2015 Mar; 59(3):1435-40. PubMed ID: 25534727
[TBL] [Abstract][Full Text] [Related]
18. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
Lam SW; Bass SN; Neuner EA; Bauer SR
Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
[TBL] [Abstract][Full Text] [Related]
20. Cadazolid for the treatment of Clostridium difficile.
Endres BT; Bassères E; Alam MJ; Garey KW
Expert Opin Investig Drugs; 2017 Apr; 26(4):509-514. PubMed ID: 28286992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
